These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25759215)

  • 1. Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.
    Martin A; Salvador F; Moreno-Bueno G; Floristán A; Ruiz-Herguido C; Cuevas EP; Morales S; Santos V; Csiszar K; Dubus P; Haigh JJ; Bigas A; Portillo F; Cano A
    EMBO J; 2015 Apr; 34(8):1090-109. PubMed ID: 25759215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma.
    Sanada T; Islam A; Kaminota T; Kirino Y; Tanimoto R; Yoshimitsu H; Yano H; Mizuno Y; Okada M; Mitani S; Ugumori T; Tanaka J; Hato N
    Laryngoscope; 2020 May; 130(5):E327-E334. PubMed ID: 31219623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
    Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L
    Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel splice variant of LOXL2 promotes progression of human papillomavirus-negative head and neck squamous cell carcinoma.
    Liu C; Guo T; Sakai A; Ren S; Fukusumi T; Ando M; Sadat S; Saito Y; Califano JA
    Cancer; 2020 Feb; 126(4):737-748. PubMed ID: 31721164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
    Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
    Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of LOX- and LOXL2-mRNA expression in head and neck squamous cell carcinomas.
    Rost T; Pyritz V; Rathcke IO; Görögh T; Dünne AA; Werner JA
    Anticancer Res; 2003; 23(2B):1565-73. PubMed ID: 12820424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3.
    Lu YJ; Deng YT; Ko HH; Peng HH; Lee HC; Kuo MY; Cheng SJ
    Cancer Sci; 2023 Oct; 114(10):3957-3971. PubMed ID: 37496288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma.
    Fukumoto I; Kikkawa N; Matsushita R; Kato M; Kurozumi A; Nishikawa R; Goto Y; Koshizuka K; Hanazawa T; Enokida H; Nakagawa M; Okamoto Y; Seki N
    J Hum Genet; 2016 Feb; 61(2):109-18. PubMed ID: 26490187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous disturbance of NHE1 and LOXL2 decreases tumorigenicity of head and neck squamous cell carcinoma.
    Hayashi Y; Miyoshi S; Watanabe I; Yano N; Nagashio K; Kaneko M; Kaminota T; Sanada T; Hosokawa Y; Kitani T; Mitani S; Choudhury ME; Yano H; Tanaka J; Hato N
    Auris Nasus Larynx; 2024 Jun; 51(3):472-480. PubMed ID: 38520980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma.
    Lv GQ; Zou HY; Liao LD; Cao HH; Zeng FM; Wu BL; Xie JJ; Fang WK; Xu LY; Li EM
    Biochem Cell Biol; 2014 Oct; 92(5):379-89. PubMed ID: 25275797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas.
    Zhan P; Shen XK; Qian Q; Zhu JP; Zhang Y; Xie HY; Xu CH; Hao KK; Hu W; Xia N; Lu GJ; Yu LK
    Med Oncol; 2012 Jun; 29(2):648-55. PubMed ID: 21519871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LOXL2 in epithelial cell plasticity and tumor progression.
    Cano A; Santamaría PG; Moreno-Bueno G
    Future Oncol; 2012 Sep; 8(9):1095-108. PubMed ID: 23030485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifactorial ERβ and NOTCH1 control of squamous differentiation and cancer.
    Brooks YS; Ostano P; Jo SH; Dai J; Getsios S; Dziunycz P; Hofbauer GF; Cerveny K; Chiorino G; Lefort K; Dotto GP
    J Clin Invest; 2014 May; 124(5):2260-76. PubMed ID: 24743148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loxl2 is dispensable for dermal development, homeostasis and tumour stroma formation.
    Kober KI; Cano A; Géraud C; Sipilä K; Mobasseri SA; Philippeos C; Pisco AO; Stannard A; Martin A; Salvador F; Santos V; Boutros M; Rognoni E; Watt FM
    PLoS One; 2018; 13(6):e0199679. PubMed ID: 29953488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
    Salvador F; Martin A; López-Menéndez C; Moreno-Bueno G; Santos V; Vázquez-Naharro A; Santamaria PG; Morales S; Dubus PR; Muinelo-Romay L; López-López R; Tung JC; Weaver VM; Portillo F; Cano A
    Cancer Res; 2017 Nov; 77(21):5846-5859. PubMed ID: 28720577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts.
    Görögh T; Quabius ES; Heidebrecht H; Nagy A; Muffels T; Haag J; Ambrosch P; Hoffmann M
    Int J Cancer; 2016 May; 138(10):2529-38. PubMed ID: 26756583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.
    Peng L; Ran YL; Hu H; Yu L; Liu Q; Zhou Z; Sun YM; Sun LC; Pan J; Sun LX; Zhao P; Yang ZH
    Carcinogenesis; 2009 Oct; 30(10):1660-9. PubMed ID: 19625348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
    Pollheimer MJ; Racedo S; Mikels-Vigdal A; Marshall D; Bowlus C; Lackner C; Madl T; Karlsen TH; Hov JR; Lyman SK; Adamkewicz J; Smith V; Moreau E; Zollner G; Eide TJ; Stojakovic T; Scharnagl H; Gruber HJ; Stauber RE; Trauner M; Fickert P
    J Hepatol; 2018 Aug; 69(2):368-377. PubMed ID: 29709678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors.
    Fong SF; Dietzsch E; Fong KS; Hollosi P; Asuncion L; He Q; Parker MI; Csiszar K
    Genes Chromosomes Cancer; 2007 Jul; 46(7):644-55. PubMed ID: 17394133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.